Literature DB >> 20356699

Carbapenem-resistant Klebsiella pneumoniae bacteremia: factors correlated with clinical and microbiologic outcomes.

May Nguyen1, Gregory A Eschenauer, Monique Bryan, Kelly O'Neil, E Yoko Furuya, Phyllis Della-Latta, Christine J Kubin.   

Abstract

We undertook a retrospective cohort study describing general outcomes and specific factors associated with positive outcomes in bacteremia due to carbapenem-resistant Klebsiella pneumoniae (CRKP). Forty-eight patients were included, of which 42% died at 30 days. Forty-two percent of patients were in septic shock at the time of the first positive blood culture, and 42% were recipients of solid organ transplants. Lack of microbiologic eradication at 7 days was independently associated with 30-day mortality. Adjunctive procedures performed for source control and microbiologic eradication at 7 days were associated with a favorable clinical response at 7 days. Time to initiation and receipt at any time of antimicrobials with in vitro activity against CRKP were not associated with improved survival. Breakthrough bacteremia occurred in 8 cases, all in patients receiving tigecycline. Our data suggest that severity of illness, rapid microbiologic eradication, and source control are crucial factors in the outcomes of patients with CRKP bacteremia. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20356699     DOI: 10.1016/j.diagmicrobio.2010.02.001

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  38 in total

1.  The combination of doripenem and colistin is bactericidal and synergistic against colistin-resistant, carbapenemase-producing Klebsiella pneumoniae.

Authors:  Meredith G Jernigan; Ellen G Press; M Hong Nguyen; Cornelius J Clancy; Ryan K Shields
Journal:  Antimicrob Agents Chemother       Date:  2012-03-19       Impact factor: 5.191

2.  Multidrug-resistant bacteria in organ transplantation: an emerging threat with limited therapeutic options.

Authors:  Gopi Patel; Meenakshi M Rana; Shirish Huprikar
Journal:  Curr Infect Dis Rep       Date:  2013-12       Impact factor: 3.725

3.  Impact of combination antimicrobial therapy on mortality risk for critically ill patients with carbapenem-resistant bacteremia.

Authors:  Stephanie N Bass; Seth R Bauer; Elizabeth A Neuner; Simon W Lam
Journal:  Antimicrob Agents Chemother       Date:  2015-04-06       Impact factor: 5.191

Review 4.  Multidrug-resistant Gram-negative bacteria in solid organ transplant recipients with bacteremias.

Authors:  Q Q Wan; Q F Ye; H Yuan
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-11-12       Impact factor: 3.267

5.  Peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO) restores carbapenem susceptibility to NDM-1-positive pathogens in vitro and in vivo.

Authors:  Erin K Sully; Bruce L Geller; Lixin Li; Christina M Moody; Stacey M Bailey; Amy L Moore; Michael Wong; Patrice Nordmann; Seth M Daly; Carolyn R Sturge; David E Greenberg
Journal:  J Antimicrob Chemother       Date:  2017-03-01       Impact factor: 5.790

Review 6.  Recipient-born bloodstream infection due to extensively drug-resistant Acinetobacter baumannii after emergency heart transplant: report of a case and review of the literature.

Authors:  Roberto Andini; Federica Agrusta; Irene Mattucci; Umberto Malgeri; Giusi Cavezza; Riccardo Utili; Emanuele Durante-Mangoni
Journal:  Infection       Date:  2015-04-01       Impact factor: 3.553

7.  IncFII Conjugative Plasmid-Mediated Transmission of blaNDM-1 Elements among Animal-Borne Escherichia coli Strains.

Authors:  Dachuan Lin; Miaomiao Xie; Ruichao Li; Kaichao Chen; Edward Wai-Chi Chan; Sheng Chen
Journal:  Antimicrob Agents Chemother       Date:  2016-12-27       Impact factor: 5.191

Review 8.  Carbapenem-resistant Enterobacteriaceae in special populations: Solid organ transplant recipients, stem cell transplant recipients, and patients with hematologic malignancies.

Authors:  Stephanie M Pouch; Michael J Satlin
Journal:  Virulence       Date:  2016-07-28       Impact factor: 5.882

9.  Risk factors for carbapenem-resistant Klebsiella pneumoniae infection and associated clinical outcomes.

Authors:  Guanqun Dai; Yanling Xu; Hui Kong; Weiping Xie; Hong Wang
Journal:  Am J Transl Res       Date:  2021-06-15       Impact factor: 4.060

10.  Patient risk factors for outer membrane permeability and KPC-producing carbapenem-resistant Klebsiella pneumoniae isolation: results of a double case-control study.

Authors:  G B Orsi; A Bencardino; A Vena; A Carattoli; C Venditti; M Falcone; A Giordano; M Venditti
Journal:  Infection       Date:  2012-10-16       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.